Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti seizure efficacy

Research output: Contribution to journalArticleScientificpeer-review

Claudia Brandt, Patricia Seja, Kathrin Töllner, Kerstin Römermann, Philip Hampel, Markus Kalesse, Andi Kipper, Peter W. Feit, Kasper Lykke, Trine Lisberg Toft-Bertelsen, Pauliina Paavilainen, Inkeri Spoljaric, Martin Puskarjov, Nanna MacAulay, Kai Kaila, Wolfgang Löscher

LanguageEnglish
JournalNeuropharmacology
Volume143
Pages186-204
Number of pages19
ISSN0028-3908
DOIs
Publication statusPublished - Dec 2018
MoE publication typeA1 Journal article-refereed

Bibliographical note

Correction
Volume: 143
Pages: 349-350
DOI: 10.1016/j.neuropharm.2018.10.012

    Research areas

  • Epilepsy, Anti-seizure drugs, Neonatal seizures, GABA, Giant depolarizing potentials, CATION-CHLORIDE COTRANSPORTERS, GIANT DEPOLARIZING POTENTIALS, WATER PERMEABILITY, PILOCARPINE MODEL, ANIMAL-MODELS, PYRAMIDAL NEURONS, DRUG DISCOVERY, KINDLED RATS, GABA ACTIONS, AQUAPORIN 4
  • 3112 Neurosciences
  • 1184 Genetics, developmental biology, physiology

External organisations

Brandt, Claudia
  • University of Veterinary Medicine Hannover
Töllner, Kathrin
  • University of Veterinary Medicine Hannover
Römermann, Kerstin
  • University of Veterinary Medicine Hannover
Hampel, Philip
  • University of Veterinary Medicine Hannover
Kalesse, Markus
  • Leibniz Universität Hannover
Kipper, Andi
  • Leibniz Universität Hannover
Feit, Peter W.
  • University of Veterinary Medicine Hannover
Lykke, Kasper
  • University of Copenhagen
Toft-Bertelsen, Trine Lisberg
  • University of Copenhagen
MacAulay, Nanna
  • University of Copenhagen
Löscher, Wolfgang
  • University of Veterinary Medicine Hannover

ID: 121999869